Disclosures for "Systemic AAV Gene Therapy Using a CNS-targeted Engineered Capsid Significantly Increases GCase Activity to Support the Potential Treatment of PD-GBA"
-
Dr. Ressler has received personal compensation for serving as an employee of Capsida Biotherapeutics.
-
Dr. McDowell has received personal compensation for serving as an employee of Capsida Biotherapeutics.
-
Mr. Wheeler has received personal compensation for serving as an employee of Capsida.
-
Ms. Thomas has received personal compensation for serving as an employee of Capsida Biotherapeutics .
-
Dr. Grigoryeva has received personal compensation for serving as an employee of Capsida Biotherapeutics.
-
Mr. Armendariz has nothing to disclose.
-
Ms. flynn has received personal compensation for serving as an employee of Capsida Biotherapeutics .
-
Dr. Acharya has received personal compensation for serving as an employee of Capsida.
-
Mr. Denis has received personal compensation for serving as an employee of Capsida Biotherapeutics. Mr. Denis has stock in Amgen Inc..
-
Mr. Tchourilov has received personal compensation for serving as an employee of Capsida Biotherapeutics. Mr. Tchourilov has stock in Capsida Biotherapeutics.
-
Dr. Tole has received personal compensation for serving as an employee of Capsida Biotherapeutics. Dr. Tole has stock in Capsida Biotherapeutics. Dr. Tole has stock in Roche.
-
Dr. Goeden has received personal compensation for serving as an employee of Capsida Biotherapeutics . Dr. Goeden has stock in Capsida Biotherapeutics . Dr. Goeden has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Flytzanis has received personal compensation for serving as an employee of Capsida Biotherapeutics, Inc.. Dr. Flytzanis has received intellectual property interests from a discovery or technology relating to health care.